Other substances

4E2RCat

inhibits protein synthesis

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

4E2RCat is an inhibitor of eIF4E-eIF4G interaction. 4E2RCat prevents the interaction between eIF4E (the cap-binding protein) and eIF4G (a large scaffolding protein), inhibiting cap-dependent translation. It significantly decreases human coronavirus 229E (HCoV-229E) replication, reducing the percentage of infected cells and intra- and extracellular infectious virus titers. 4E2RCat inhibits coronavirus replication in a dose- and time-dependent manner.

Regarding SARS-CoV-2, our AIM tool found tha data that abacavir could help against SARS-CoV-2 by modulating its interactors. 

4E2RCat

 

Structure image - 4E2RCat

C22H14ClNO4S2

Supporting references

Link Tested on Impact factor Notes Publication date
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Small molecule 		in silico 42.78 Apr/30/2020
Export (.csv)